KAESIDE UNACHUKWU: Open Payments
NPI 1306477906 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,626 in 76 payments from 11 companies in 2025. Trend: 2023 $3,217 · 2024 $2,343 · 2025 $3,626
Food & beverage: $3,626
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $787 |
| E.R. Squibb & Sons, L.L.C. | 11 | $562 |
| Otsuka America Pharmaceutical, Inc. | 7 | $532 |
| Axsome Therapeutics, Inc. | 5 | $399 |
| Teva Pharmaceuticals USA, Inc. | 6 | $279 |
| Janssen Pharmaceuticals, Inc | 7 | $278 |
| Supernus Pharmaceuticals, Inc. | 10 | $238 |
| Alkermes, Inc. | 4 | $236 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Noven Therapeutics, LLC | 1 | $107 |
Products named: CAPLYTA, COBENFY, Auvelity, INVEGA SUSTENNA, ABILIFY MAINTENA, REXULTI, Qelbree, UZEDY.
Industry payments across TX — which companies pay providers there.
